Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment

The Chinese University of Hong Kong

Status: Active, not recruiting

Conditions: IVF; Intracytoplasmic Sperm Injection

Treatments: Drug: Buscopan 20 milligrams/ML Injectable Solution

Study type: Interventional

Funder types: Other

Identifiers

NCT04751084

2019.109-T

Details and patient eligibility

About

To determine if the use of Buscopan in patients undergoing IVF/ICSI treatment with high uterine contraction frequency prior to embryo transfer has a higher live birth rate.

Enrollment: 675 patients

Sex: Female

Ages: Under 42 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women undergoing embryo transfer in either fresh or frozen cycles

Exclusion criteria

• Women aged > 42 years old
• Women with factors which will affect uterine contractility
• congenital uterine anomaly
• acquired uterine pathology such as myoma >5cm, adenomyosis >5cm or endometrial polyp
• Women with presence of hydrosalpinx
• Women undergoing pre-implantation genetic test in IVF cycles
• History of allergy to misoprostol , Buscopan® or same group of drug
• Contraindication to the use of Buscopan® e.g. glaucoma, myasthenia gravis, tachycardia, megacolon
• Women who are on other smooth muscle relaxant other than Buscopan®

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

675 participants in 2 patient groups, including a placebo group

treatment group

Active Comparator group

Description:

20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer

Treatment:

Drug: Buscopan 20 milligrams/ML Injectable Solution

control group

Placebo Comparator group

Description:

2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer

Treatment:

Drug: Buscopan 20 milligrams/ML Injectable Solution